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Summary Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside analogue. As part of a series of studies to determine the maximum
tolerated dose (MTD) of gemcitabine and the most appropriate schedule, a two-centre phase I study of gemcitabine was undertaken in
patients with advanced refractory solid tumours using a once every 2 weeks schedule. Fifty-two patients were entered into the study at 14
different dose levels (40-5700 mg m-2). Weekly evaluations for toxicity were performed and the MTD for this once every 2 weeks schedule
was 5700 mg m-2. The dose-limiting toxicity was myelosuppression, with neutropenia being most significant. Other toxicities were nausea,
vomiting, fever and asthenia. One minor response was seen in a heavily pretreated breast cancer patient treated at 1200 mg m-2. Preclinical
studies suggest that the efficacy of gemcitabine is more schedule than dose related, and it is concluded that this is not the most appropriate
dosing schedule for gemcitabine. However, this study demonstrates the safety profile of gemcitabine, as doses overfourfold greaterthan that
recommended for the weekly schedule of 1000 mg m-2 could be tolerated.
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Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside
analogue. It is a potent and quite specific deoxycytidine analogue,
with 1 ng ml-l of gemcitabine inhibiting growth of CCRF-CEM
human leukemia cells by 50% (Grindey et al, 1990). Initial precin-
ical testing using adaily dosing schedule wasdisappointing because
there was greater toxicity than with an intermittent schedule. A
staggered dosing schedule (e.g. every 3-4 days) provided excellent
anti-tumour activity and a broad therapeutic index against a broad
spectrum of murine solid tumour, murine leukaemia and human
tumour xenograft models (Grindey et al, 1990).
Cytosine arabinoside (ara-C) is also adeoxycytidine analogue. It
has proven activity in several haematological malignancies but,
unlike gemcitabine, it does not show activity in solid tumours.
Plunkett and colleagues (1989) have conducted extensive cellular
pharmacology studies to account for these apparent differences in
anti-tumour effect between ara-C and gemcitabine. Inside the cell,
both compounds are converted to the active triphosphate metabolite
by deoxycytidine kinase. However, in several different cell types
the accumulation of gemcitabine triphosphate is more rapid and
greatly exceeds the concentrations of ara-C triphosphate achieved
under similarconditions. In addition, the tumourcells can eliminate
ara-C triphosphate much morerapidly than thegemcitabinetriphos-
phate. The reason thatgemcitabine triphosphate accumulates within
thecell atcomparatively high levels andforalongperiod appears to
be due to three novel mechanisms of self-potentiation, which have
been discussed previously (Carmichael et al, 1996).
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To determine a suitable dose and schedule for phase II studies
the following phase I schedules have been studied: daily x 5 every
3 weeks; twice weekly x 6 every 4 weeks; weekly x 3 every 4
weeks and this once every 2 weeks schedule. The last schedule
was chosen in order to determine a maximum tolerated dose
(MTD) forgemcitabine using an intermittent schedule. Although a
safe starting dose for intermittent schedules of 20 mg m-2 was
predicted, data from the weekly x 3 every 4 weeks phase I study
(Abbruzzese et al, 1991) allowed a starting dose of40 mg m-2 for
this study.
MATERIALS AND METHODS
Patients
Patients with solid tumours had to have advanced refractory
disease that was not amenable to conventional therapy or investi-
gational therapy of higher potential efficacy or advanced disease
for which no standard therapy existed. Patients had to have recov-
ered from the toxic effects ofany previous therapy. Patients had to
be aged 18-75 years with aWHO performance status of0-2. They
had to have adequate organ function and normal prothrombin
and partial thromboplastin times. Patients with haematological
malignancies and those who had received previous therapy
with fluorinated nucleotides, apart from 5-fluorouracil and its
derivatives, were excluded. Patients receiving > 10 mg day-' of
prednisone (or equivalent) were excluded, unless this dose had
been established more than 1 month before entry. All patients had
to give written informed consent before entering the study, which
was approved by local ethics committees.
*Deceased, formerly at Centre Leon Berard, Lyon, France
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Table 1 Patient characteristics
Total entered (male/female)
Median age (years)
Median WHO performance status (range)
Prior therapy
Radiotherapy only
Chemotherapy only
Radio- and chemotherapy
None except surgery
None
Tumour types
Head and neck
Colorectal
Breast
Non-small-cell lung
Ovary
Soft tissue sarcoma
Stomach
Bladder
Cervix
Melanoma
Mesothelioma
Oesophagus
Uterus
Unknown primary
Others
52 (22/30)
54.5 (30-73)
1 (0-2)
13
34
1
3
12
9
8
3
3
4
2
1
2
2 1
1
2
Design
This phase I, dose-ranging, open-label, non-randomized study was
performed to determine the MTD of gemcitabine given as a 30-
min infusion once every 2 weeks. Secondary objectives of the
study were to determine the toxicities of gemcitabine using this
schedule, a safe dose for phase II evaluation, the basic pharmaco-
kinetics and to document any possible anti-tumour effect.
Gemcitabine was administered as an i.v. 30-min infusion. The
first dose level was 40 mg m-2. A minimum of three patients was
entered at each dose level and doses could be escalated by 100%
increments until grade 1 toxicity was seen. The MTD was defined
as the highest dose that can be safely administered to a patient
producing tolerable, manageable and reversible toxicity.
Pretreatment evaluation included full history and clinical exam-
ination as well as assessment ofperformance status and weight. In
addition, haematology and biochemistry tests, electrocardiogram
(ECG), chest radiograph, urinalysis and assessment of extent of
disease were performed.
Patients who received treatment for 6 weeks were evaluable
for response and all patients receiving at least one injection of
gemcitabine were evaluable fortoxicity.
RESULTS
Patient characteristics
Fifty-two patients were entered into the study; all received at least
one dose ofgemcitabine and were therefore evaluable fortoxicity.
Overall, 221 injections of gemcitabine were given. Twenty-three
patients completed at least three injections, had measurable or
evaluable disease and were therefore evaluable for response. The
characteristics of all 52 patients are summarized in Table 1.
Seventy per cent of patients were aged 2 50 years. Patients were
entered with a wide range of different tumours, head and neck,
Table 2 Patients and courses per dose level
Dose (mg m-2) Patients Initial Subsequent Total
courses courses courses
40 3 3 10 13
80 3 3 4 7
160 3 3 5 8
320 4a 3 11 14
640 6 5 10 15
960 3 3 7 10
1200 3 3 12 15
1500 5 5 32 (2b) 37
1875 5 5 19 24
2345 3 3 11 14
2930 4 4 10 14
3650 4 4 7 11
4560 3 3 11(2b,2c) 14
5700 5 5 (2b) 20 (3b, 3c) 25
Total 52 52 169 221
aincluding one patient with dose escalation; b60-min infusion; c120-min
infusion.
Table 3 Grade 3 and 4 haematological toxicity (maximum per patient)
Dose Evaluable WHO grade
(mg m-2) patients
Leucocytes Neutrophils Platelets
3 4 3 4 3 4
< 1200 18 1 0 1 0 1 0
1200 3 0 0 1 0 0 0
1500 2 1 0 2 0 0 0
1875 5 0 0 1 0 1 0
2345 3 0 0 0 0 0 0
2930 4 0 0 0 0 0 0
3650 3 0 0 0 0 0 0
4560 3 0 0 0 0 0 0
5700 5 2 0 0 3 0 1
colorectal and breast tumours being the most common. Most
patients had received previous surgery, chemotherapy or
chemotherapy plus radiotherapy, and only four (8%) patients had
not received any previous chemotherapy orradiotherapy.
Laboratory toxicity
Thirteen dose escalations were required to define the MTD (Table
2). All toxicities were WHO graded. Overall changes in laboratory
parameters were mild apart from at the highest dose. Some mild
myelosuppression was seen in the 960-1875 mg m-2 dose range,
but significant toxicity was not seen until 5700 mg m-2. The dose-
limiting toxicity was neutropenia, appearing rather abruptly at the
5700 mg m-2 dose level, in which three of five patients experi-
enced grade 4 toxicity (Table 3). The neutropenic nadir tended to
occur 7 days after dosing but was short-lived and usually recov-
ered to > 1 x 109 1-1 within a week.
Leucopenia was mild with the highest toxicity being grade 3
(four patients, i.e. 8%), and in two of these patients leucopenia
occurred at the highest dose (Table 3). Thrombocytopenia was
mild, withonly threepatients (6%) havinggrade 3 or4 (onepatient
with grade 3 at 960 mg m-2, another grade 3 at 1875 mg m-2 and
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Table 4 Non-haematological and liver function
Numbers with WHO grade 1-3 toxicity
<1200 1200-2345 2930-4560 5700 All
(n =19a) (n = 16) (n = 11) (n = 5) (n = 51)
Increased LFT 12 9 8 5 34
Nausea/vomiting 4 9 4 5 22
Fever 2 2 2 1 7
Alopecia 0 2 0 3 5
Diarrhoea 0 1 2 1 4
Cutaneous 1 0 0 3 4
Neurological 2 1 1 2 6
Cardiac rhythm 0 0 1 1 2
aNo follow-up data in one patient. LFT, liverfunction tests.
one patient grade 4 at 5700 mg m-2) (Table 3). The platelet nadir
occurred at about 10 days but again was short-lived. Anaemia was
also seen and seemed to be dose related as the only grade 4 toxici-
ties occurred at the highest dose of 5700 mg m-2, but it did not
appear to be cumulative. Myelosuppression appeared to be dose
related because ofthe myelosuppression seen at 5700 mg m-2.
One common laboratory abnormality was a transient rise in
hepatic transaminases, with 66% ofpatientshaving 2grade 1 rise in
serum aspartate aminotransferase (AST). The increases were gener-
ally mild (22patients withgrade 1; ten with grade 2; two withgrade
3; zero with grade 4). AST seemed to be a more sensitive indicator
than the serum alanine aminotransferase (ALT). The increases
resolved within a few days and did not worsen with subsequent
dosing. There may be a dose relationship for this effect because
more patients at the higher doses had increases in transaminases,
although the severity of the increase was no greater than at lower
doses (Table 4). Raised bilirubin was rare (four patients with grade
1 and one patient grade 2) and only two patients seemed to show a
temporal relationship to gemcitabine, although both patients had
livermetastases (onegrade 1 at40 mg m-2 andone at 1875 mg m-2).
Serum creatinine was raised in six patients, although increases
were mild, with five patients developing a grade 1 rise and one
grade 2. There was no clear dose relationship because, although
five of these six patients received a dose 2 1875 mg m-2, none of
the patients treated at the highest level of 5700 mg m-2 developed
any WHO grade changes in creatinine level. Ofthese six patients,
three developed a grade 1 rise in creatinine just before they were
taken offthe study because ofprogressive disease. Two developed
a grade 1 rise during therapy, which returned to grade 0 despite
receiving further gemcitabine. The only patient to develop a grade
2 rise developed this 19 days after gemcitabine administration
after he had been prescribed diuretics for ascites.
Owing to the need for dilution, when higher doses were admin-
istered the infusion duration was extended to 60 or 120 min in
some patients (Table 2). Although the numbers ofcycles adminis-
tered with a longer infusion time is small, there was no evidence of
increased toxicity with the longer infusion times. Indeed, at the
highest dose level of5700 mg m-2, the only cycles with grade 3 or
4 leucopenia or thrombocytopenia were those administered over a
30-min infusion time.
Symptomatic toxicity
Non-laboratory toxicity at all doses is shown in Table 4. Overall,
the toxicity was again mild, with no grade 4 toxicity and only eight
(15%) patients having any grade 3 toxicity (four nausea and
vomiting; two diarrhoea; two neurotoxicity). Indeed, the only
grade 2 symptomatic toxicities seen in more than three patients
were nausea and vomiting (11 patients) and fever (six patients).
Asthenia was commonly reported (23 patients, 44%) and
seemed to be dose related, with four out of five patients reporting
it at 5700 mg m-2, but it did not appear to be cumulative in nature.
Four patients were removed from the study because of possible
gemcitabine-related adverse events: anxiety (80 mg m-2, after one
injection); asthenia (1200 mg m-2, after five injections); peroneal
nerve paralysis (1500 mg m-2, after 11 injections); and constipa-
tion (2930 mg m-2, after two injections). Two patients died during
this study. A 53-year-old man with head and neck carcinoma
developed pneumonia 1 day after the first injection at 320 mg m-2.
He had an elevated white blood cell count and died 1 day later
from septicaemia. The relationship ofgemcitabine to this infection
and death is unlikely. A 61-year old man with mesothelioma
became progressively dysarthric and developed paraplegia after
Table 5 Summary of dose-limiting toxicities in four dosing schedules of gemcitabine
Dosing schedule Recommended phase 11 dose Toxicity profile Reference
Daily x 5 every 3 weeks Significant toxicity Non-haematological O'Rourke et al (1994)
2 7 mg m-2, maximum dose (fever, flu-like, hypotension)
given 12 mg m-2
Twice-weekly x 6 every 4 weeks 65 mg m-2 Thrombocytopenia dose- Poplin et al (1992)
limiting, non-
haematological toxicity
(fatigue, fever, flu-like,
skin rash)
Weekly x 3 every 4 weeks 790 mg m-2 Myelosuppression dose- Abbruzzese (1991)
limiting, non-
haematological toxicity
minimal
Once every 2 weeks 4560 mg m-2 Myelosuppression dose- This paper
limiting, asthenia, other
non-haematological
toxicity maintained
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the fourth injection at 2930 mg m-2. Nystagmus, paraparesis and
hypothermia were also observed. He later developed dyspnoea,
generally deteriorated and died. A post-mortem showed signifi-
cant pulmonary oedema but no abnormality ofthe central nervous
system, including normal histology of the Purkinje cells. A causal
relationship to gemcitabine treatment could not be excluded. Other
unusual toxicities included cramps in fingers at 5700 mg m-2 in
one patient and painful burning in the skin of the extremities and
hyperpigmentation at 5700 mg m-2 in one patient.
Again, there was no evidence that the toxicity was increased in
thecycles when gemcitabine was administered over 60 or 120 min
compared with 30 min.
Response
Overall, 27 patients had measurable or evaluable disease.
However, four of these patients were inevaluable for response.
Early progressive disease developed in one patient after only one
injection and in three patients after two injections. Of the 23
patients evaluable for response, there was one minor response in a
patient with breast cancer. This patient was a 62-year-old woman
who had a mastectomy and adjuvant 5-flourouracil, adriamycin,
cyclophosphamide (FAC) and CMF for node-positive breast
cancer7 yearspreviously. Sherelapsed4 years later andhad radio-
therapy, which resulted in a minor response that lasted 1.9 months.
She was then treated with aminoglutethemide followed by four
separate different combination chemotherapy regimens but had
progressed through all these.
DISCUSSION
This study describes our clinical experience with gemcitabine
using a once every 2 weeks schedule. Myelosuppression (mainly
neutropenia) was the dose-limiting toxicity. Other laboratory toxi-
cities seen were mild transient rises in hepatic transaminases and
mild hyperbilirubinaemia. The most common non-haematological
toxicity was nausea and vomiting, which occurred in half of the
patients but was generally mild.
Toxicities of particular importance to the patient, such as
mucositis and alopecia, were not a problem. There was no WHO
grade 3 or 4 alopecia. Three out offourpatients with grade 3 nausea
and vomiting received gemcitabine at the two highest dose levels
(4560 mg m-2and5700 mg m-2), but there was no grade 4 toxicity.
Asthenia was a common complaint, being reported in 23 out of
52 (44%) patients. Itappeared to be dose related as four out offive
patients at the highest dose were affected. The asthenia was
usually mild but the patient with a minor response was removed
after six courses because ofasthenia.
One patient treated at 2930 mg m-2 developed probable neuro-
logical toxicity with dysarthria and paraplegia. He deteriorated
and died, but no abnormality of the central nervous system was
found at post-mortem. Similar clinical pictures have been seen
with the use ofhigh-dose ara-C (Salinsky et al, 1983). However, in
these cases typical histological abnormalities of the Purkinje cell
have been seen. Although a causal relationship to gemcitabine
could not be excluded, another three patients were treated at
2930 mg m-2 and a further 12 patients athigherdoses and no other
similar neurological toxicity was seen, although two patients at
5700 mg m-2developed grade 2 paraesthesiae.
Gemcitabine has shown marked schedule dependency in its
toxicity profile. The initial phase I studies using a 30-min infusion
have shown very different toxicities and marked differences in
MTD in the four schedules tested (Table 5).
When the drug was given daily x 5 every 3 weeks, significant
toxicity was seen at doses .7 mg m-2 (O'Rourke et al, 1994), non-
haematological toxicity in the form offever and flu-like symptoms
and severe hypotension being the main problems. That study was
stopped because the non-haematological toxicity made it an
unattractive schedule. The maximum dose given was 12 mg m-2.
When gemcitabine was given twice weekly x 6 every 4 weeks,
the MTD was 65 mg M-2day-' (Poplin et al, 1992), thrombo-
cytopenia was dose limiting and non-haematological toxicities
such as fatigue, fever, flu-like symptoms and skin rash were
common. This schedule has been used more recently (Lund et al,
1994a) in a phase II setting at a dose of90 mg m-2 in chemonaive
patients, and again flu-like symptoms were dose limiting.
When gemcitabine was given weekly x 3 every 4 weeks, the
MTD was 790 mg m-2. The dose limiting toxicity was myelosup-
pression and non-haematological toxicity was minimal
(Abbruzzese et al, 1991).
In our study using a once every 2 weeks schedule, the MTD was
5700 mg m-2 i.e. a 95-fold increase in dose per course than the
maximum given on the daily x 5 schedule. The dose-limiting
toxicity was myelosuppression and, in keeping with the other
less frequent schedules, the non-haematological toxicities, such as
hypotension andflu-like symptoms, were notaproblem. Obviously,
this schedule enabled a much higher dose of gemcitabine to be
given, and this may account forthe increased incidence ofasthenia.
Although the starting dose for this study was above that predicted
from animal studies because ofthe progress of other phase I trials,
it still took 13 dose escalations to determine the MTD. Pharmaco-
kinetically determined dose escalations might have allowed more
aggressive dose escalation and hence fewer steps.
Overall, gemcitabine was well tolerated using this once every 2
weeks schedule, although the subjective feeling ofasthenia was of
clinical significance but difficult to quantify. However, preclinical
data suggest that more frequent administration of gemcitabine is
required for optimal activity (Grindey et al, 1990). In addition,
pharmacokinetic data from both this study (Peters et al, 1990;
manuscript in preparation) and the phase I weekly study
(Abbruzzese et al, 1991) suggested that saturation of the active
metabolite gemcitabine 5'-phosphate accumulation occurs in
peripheral blood mononuclear cells when plasma gemcitabine
levels exceed 20gmol 1-1. This level can be achieved by a dose of
350-1000 mg m-2using a30-mininfusion and so these levels were
greatly exceeded in this study.
However, the half-life of gemcitabine is short (Plunkett et al,
1989) (t12a 8 min) and so the optimal duration ofinfusion may be
considerably longerthan 30 minto achieve maximal production of
the active triphosphate metabolite. Thus, alternative schedules and
longer durations ofinfusion should be and are being investigated.
Two responses were seen in the phase I weekly schedule, and in
view of this and pharmacokinetic data suggesting that the blood
levels achieved were adequate to potentially achieve maximal
loading ofgemcitabine triphosphate, it was decided not to proceed
with the once every 2 weeks schedule. Instead, the weekly
schedule has been developed further. Clinical responses have been
seen using a weekly x 3 every 4 weeks 30-min infusion in non-
small-cell lung cancer (Anderson et al, 1994; Abratt et al, 1994,
Gatzemeier et al, 1996), breast cancer (Carmichael et al, 1995),
pancreatic cancer (Carmichael et al, 1996) and ovarian cancer
(Carmichael et al, 1996 and Lund et al, 1994b).
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This study does, however, confinn the wide therapeutic window
of gemcitabine, as doses over fourfold of that recommended for
use with the weekly schedule (1000 mg m-2) could be tolerated. In
addition, this 2-weekly schedule is now being used in the clinic in
combination with other agents to avoidtreating patients atthe time
ofthe nadiron day 8 and to try to optimize thecombinations (Lilly,
data on file).
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